Home › Funds › Frazier Life Sciences Management, L.P. › KRYS

Frazier Life Sciences Management, L.P. position in KRYS

KRYSTAL BIOTECH INC · Health Care

Frazier Life Sciences Management, L.P. reported holding 481,307 shares of KRYS (KRYSTAL BIOTECH INC) in its Q2 2026 13F filing — a position valued at US$178.9M, representing 3.90% of its reported portfolio and ranking #7 among its reported holdings. Frazier Life Sciences Management, L.P. has disclosed KRYS holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)481.31K sh
Reported value held$178.89M
Portfolio Weight3.90%
First reportedQ3 2023
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Frazier Life Sciences Management, L.P.'s KRYS position evolved

Frazier Life Sciences Management, L.P. first disclosed a stake in KRYS in Q3 2023 at 988,460 shares (US$114.7M). The position peaked in Q2 2024 at 988,460 shares, worth US$181.5M. Across 12 filings, Frazier Life Sciences Management, L.P. increased the stake 0 time(s), trimmed it 4 time(s) and left it unchanged 7 time(s). The most recent filing (Q2 2026) shows 481,307 shares valued at US$178.9M. Notable position changes include a 29% trim in Q4 2025 (shares rose 5% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 988.46K $114.66M New
Q4 2023 988.46K $122.63M Hold
Q1 2024 988.46K $175.88M Hold
Q2 2024 988.46K $181.52M Hold
Q3 2024 988.46K $179.93M Hold
Q4 2024 788.46K $123.52M Reduce
Q1 2025 688.46K $124.13M Reduce
Q2 2025 688.46K $94.64M Hold
Q3 2025 688.46K $121.53M Hold
Q4 2025 488.46K $120.42M Reduce
Q1 2026 481.31K $124.33M Reduce
Q2 2026 481.31K $178.89M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About KRYS and 13F data

KRYS (KRYSTAL BIOTECH INC) is a Health Care company. 48 other funds we track also report a position in KRYS — the largest reported positions include Avoro Capital Advisors LLC (US$1.07B), Soleus Capital Management, L.P. (US$349.1M), Hood River Capital Management LLC (US$246.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding KRYS

All KRYS fund holders →

FAQ

How long has Frazier Life Sciences Management, L.P. held KRYS?

Frazier Life Sciences Management, L.P. has disclosed KRYS holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Frazier Life Sciences Management, L.P.'s current position in KRYS?

As of Q2 2026, Frazier Life Sciences Management, L.P. holds 481.31K shares of KRYS (KRYSTAL BIOTECH INC), valued at $178.89M, representing 3.90% of its reported portfolio and ranking #7.

Has Frazier Life Sciences Management, L.P. been buying or selling KRYS?

In the latest 13F filing (Q2 2026), Frazier Life Sciences Management, L.P. held unchanged its position in KRYS. The position peaked in Q2 2024 at 988.46K shares.

Which other funds hold KRYS?

Other major institutional holders of KRYS include Avoro Capital Advisors LLC, Soleus Capital Management, L.P., Hood River Capital Management LLC, among 48 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.